Shots:

• The launch of Idacio is based on its MAA approval by EC for all indications of the reference product in therapy areas of rheumatology- dermatology and gastroenterology
• The approval by EC follows EMA’s recommendation of product based on P-III study results assessing PK- safety- and immunogenicity with the reference product
• Idacio is a mAb TNF inhibitor- targeted for autoimmune disorders- is available in pre-filled syringe- pre-filled pen and vial presentations. AbbVie and Fresenius Kabi collaborated to commercialize Idacio with its expected launch in September 2023

Ref: Fresenius Kabi| Image: Mississauga News